Vaxil Bio lowers unit price for $350,000 placement

Executive Summary

• Vaxil Bio Ltd. has revised the terms of its previously announced non-brokered private placement, increasing the size of the offering to up to 3,111,111 units.
• The company intends to raise gross proceeds of up to $350,000 at a price of 11.25 cents per unit, with net proceeds designated for general corporate purposes.
• The offering is expected to close on or around December 4, 2025, subject to TSX Venture Exchange approval and other standard conditions.

Key Details

• Offering Structure: Non-brokered private placement of up to 3,111,111 units.
• Price: 11.25 cents per unit.
• Gross Proceeds: Up to $350,000.
• Unit Composition: Each unit consists of one common share and one share purchase warrant.
• Warrant Terms: Each warrant entitles the holder to acquire one additional share at an exercise price of 15 cents per share for a period of five years following closing.
• Use of Proceeds: General corporate purposes.
• Finder’s Fees: The company agreed to pay cash commissions of up to 8% of gross proceeds and issue non-transferrable warrants equal to up to 8% of the aggregate number of units issued.
• Hold Period: A hold period of four months and one day applies to the units, underlying shares, warrants, and finders' warrants from the date of issue.
• Closing Conditions: Subject to approval by the TSX Venture Exchange and other customary conditions.
• Expected Closing Date: On or around December 4, 2025.

Notable Quotes

• None provided in the text.